Arca
Skip to content

Combogesic (acetaminophen/ibuprofen): Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See NDA 215320's history or AFT Pharmaceuticals's company page.

On Jun 30, 2022, FDA declined to approve Combogesic (acetaminophen/ibuprofen) (NDA 215320) from AFT Pharmaceuticals Ltd. in its present form, citing nonclinical. The application was later approved.

  • Letter date: Jun 30, 2022
  • Application: NDA 215320
  • Since then: Approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Nonclinical

The Letter

Text from openFDA

You have not provided adequate toxicological risk assessments for leachables over the 5 mcg/day qualification threshold. We acknowledge your original approach in utilizing a ‘oxicological threshold of concern of 120 mcg/day as recommended in ICH M7. However, t...… openFDA did not return the full text just now. Open it in the letter search.

AFT Pharmaceuticals's Other Letters

Newest first

Record

Company
AFT Pharmaceuticals Ltd.
Application
NDA 215320
Status in openFDA
Approved
Review division
Office of Neuroscience

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.